Elizabeth Crowley sold $526k of CLDX
SR. VP & CPDO at Celldex Therapeutics, Inc.. 15,000 shares at an average of $35.06, traded Jun 7, 2024, filed Jun 11, 2024.
Score components
- +15RoleOfficer
- +18Trade size$526k at market
- +20Share of holdings soldSold 62% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-016345, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 7, 2024 | MOption exercise Common Stock | +7,500 | $10.38 | $78k | 16,574 | Jun 11, 2024 |
| Jun 7, 2024 | MOption exercise Common Stock | +7,500 | $9.02 | $68k | 24,074 | Jun 11, 2024 |
| Jun 7, 2024 | SOpen-market sale Common Stock | -15,000 | $35.06 | $526k | 9,074 | Jun 11, 2024 |
| Jun 7, 2024 | MOption exercise Incentive Stock Option (Right to Buy)derivative | -7,500 | $0.00 | $0 | 76,500 | Jun 11, 2024 |
| Jun 7, 2024 | MOption exercise Incentive Stock Option (Right to Buy)derivative | -7,500 | $0.00 | $0 | 0 | Jun 11, 2024 |
Related signals
Other insiders at Celldex Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $121k 4,166 shares | -12% | |
| 38Weak | CLDXsell Celldex Therapeutics, Inc. | Richard M. Wright SR. VP & CCO | $1.2M 49,298 shares | -70% | |
| 15Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $19k 771 shares | -2% | |
| 45Moderate | CLDXbuy Celldex Therapeutics, Inc. | Anthony S Marucci PRESIDENT & CEO | $308k 11,500 shares | +40% | |
| 60Notable | Celldex Therapeutics, Inc. | Elizabeth Crowley SR. VP & CPDO | $1.0M 30,000 shares | -77% | |
| 52Moderate | Celldex Therapeutics, Inc. | Samuel Bates Martin SVP AND CFO | $608k 17,172 shares | -38% | |
| 75Notable | Celldex Therapeutics, Inc. | Diane C. Young SVP, CHIEF MEDICAL OFFICER | $1.6M 45,000 shares | -96% | |
| 33Weak | Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $269k 8,006 shares | -24% | |
| 60Notable | Celldex Therapeutics, Inc. | Richard M. Wright SR. VP & CCO | $1.6M 46,844 shares | -69% | |
| 60Notable | Celldex Therapeutics, Inc. | Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | $2.0M 58,369 shares | -81% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.